Serum paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis

International Journal of Clinical Practice

Volumn 62, Issue 7, 2008, Pages 1050-1055

  Aslan, M ^a,b   Horoz, M ^b   Nazligul, Y ^b   Bolukbas, C ^b   Bolukbas, F F ^b   Selek, S ^b   Aksoy, N ^b   Erel, O ^b  

^a Harran University ^*  (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; LIPID HYDROPEROXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM; SPECTROPHOTOMETRY;

ADULT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CLINICAL ENZYME TESTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 44849132617     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01206..x     Document Type: Article

References (36)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002 2 : 395 403.
2. Garcia-Monzon C, Moreno-Otero R, Pajares JM et al. Expression of a novel activation antigen on intrahepatic CD8+ T lymphocytes in viral chronic active hepatitis. Gastroenterology 1990 98 : 1029 35.
3. Koziel MJ, Dudley D, Wong JT et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992 149 : 3339 44.
4. Clot P, Tabone M, Arico S, Albano E. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut 1994 35 : 1637 43.
5. Buljevac M, Romic Z, Vuceliæ B, Baniæ M, Krznaric Z, Plesko S. Serum selenium concentration in patients with liver cirrhosis and hepatocellular carcinoma. Acta Med Croatica 1996 50 : 11 4.
6. Canales A, Sanchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc) 2003 121 : 537 48.
7. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993 211 : 871 9.
8. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999 19 : 330 5.
9. Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991 86 : 193 6.
10. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995 15 : 1812 8.
11. Paragh G, Seres I, Balogh Z et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998 80 : 166 70.
12. Sutherland WH, de Jong SA, Walker RJ. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 2004 19 : 75 82.
13. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993 294 : 829 34.
14. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990 1044 : 275 83.
15. Burlina A, Galzigna L. Serum arylesterase isoenzymes in chronic hepatitis. Clin Biochem 1974 7 : 202 5.
16. Ferre N, Camps J, Prats E et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002 48 : 261 8.
17. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005 11 : 7351 4.
18. Ferre N, Marsillach J, Camps J et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006 45 : 51 9.
19. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
20. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983 35 : 1126 38.
21. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992 30 : 391 5.
22. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999 300 : 58 62.
23. Parola M, Robino G. Oxidative stress related molecules and liver fibrosis. J Hepatol 2001 35 : 297 306.
24. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003 417 : 3 11.
25. Hagen TM, Huang S, Curnutte J et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994 91 : 12808 12.
26. Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol 2001 35 : 613 8.
27. Kasai H. Analysis of a form of oxidative DNA damage 8-hydroxy-20- deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997 387 : 147 63.
28. Mackness B, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991 286 : 152 4.
29. Shih DM, Gu L, Xia YR et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998 394 : 284 7.
30. Kondo A, Li J, Manabe M, Saito K, Kanno T, Maekawa M. Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations. J Atheroscler Thromb 2003 10 : 72 8.
31. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001 21 : 473 80.
32. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmp SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998 101 : 1581 90.
33. Gil F, Pla A, Gonzalvo MC, Hernandez AF, Villanueva E. Rat liver paraoxonase: subcellular distribution and characterization. Chem Biol Interact 1993 87 : 149 54.
34. Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 1998 12 : 61 9.
35. Baskol M, Baskol G, Deniz K, Ozbakir O, Yucesoy M. A new marker for lipid peroxidation: serum paraoxonase activity in non-alcoholic steatohepatitis. Turk J Gastroenterol 2005 16 : 119 23.
36. Ferre N, Camps J, Cabre M, Paul A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001 9 : 997 1000.